Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenografts

Matilde Micillo, Beatrice Pirajno, Maria Chiara Montalbano, Giulia Giuffrè, Francesco Vallone, Giulia Omezzolli, Amelia Fascì, Nahal Nabelsi, Victor Navarro-Tableros, Elisabetta Bolli, Samir Mouhssine, Riccardo Moia, Candida Vitale, Gianluca Gaidano, Brian Lannutti, Katti Jessen, Tiziana Vaisitti, Silvia Deaglio

Blood (2025) 146 (Supplement 1): 7063.

https://doi.org/10.1182/blood-2025-7063

Published: 2025

Journal Articles

Harnessing repressive LEF1/β-catenin complexes to overcome drug resistance in chronic lymphocytic leukemia

Kadriye Nehir Cosgun, Takeshi Ito, Mark Robinson, Esma Fera, Pranav Mishra, Jodi Forward, Prajish Iyer, Lili Wang, Tiziana Vaisitti, Silvia Deaglio, Maike Buchner, Hai-Hui Xue, Matthew S Davids, Markus Müschen

Blood (2025) 146 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2025-5659

Published: 2025

Journal Articles

PD-1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient-derived xenograft models In Vivo

Ivan Negara, Esther Sathya Bama Benjamin, Giulia Felician, Claudio Martines, Marija Vujovikj, Tiziana Vaisitti, Silvia Deaglio, Aleksandar Dimovski, Luca Laurenti, Dimitar Efremov

Blood (2025) 146 (Supplement 1): 2104.

https://doi.org/10.1182/blood-2025-2104

Published: 2025

Journal Articles

Toward a new paradigm for CLL treatment

Silvia Deaglio

Blood (2024) 144 (18): 1849–1850.

https://doi.org/10.1182/blood.2024025896

Published: 2024

Journal Articles

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

Matilde Micillo, Lorenzo Brandimarte, Giulia Omezzolli, Nadia Bertola, Francesco Edoardo Vallone, Andrea Iannello, Chiara Lavarello, Nicole Grinovero, Giulio Ferrero, Kevin Mellert, Peter Moller, Nicoletta Vitale, Silvia Bruno, Richard R. Furman, John N. Allan, Andrea Petretto, Silvia Deaglio, Silvia Ravera, Tiziana Vaisitti

Blood (2023) 142 (Supplement 1): 6115.

https://doi.org/10.1182/blood-2023-179164

Published: 2023

Journal Articles

CXCR4 Loss Reduces the Local Growth of Richter Syndrome Murine and Patient-Derived Xenograft Models and Impairs BCR and VLA-4 Activation

Claudio Martines, Supriya Chakraborty, Antonella Zucchetto, Erika Tissino, Vincenzo Guastafierro, Marija Vujovikj, Tiziana Vaisitti, Silvia Deaglio, Luca Laurenti, Aleksandar J Dimovski, Valter Gattei, Dimitar G Efremov

Blood (2023) 142 (Supplement 1): 80.

https://doi.org/10.1182/blood-2023-179183

Published: 2023

Journal Articles

Chemoresistance pathways in DLBCL

Silvia Deaglio

Blood (2023) 142 (11): 943–944.

https://doi.org/10.1182/blood.2023021142

Published: 2023

Journal Articles

Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo

Claudio Martines, Supriya Chakraborty, Marija Vujovikj, Stefania Gobessi, Tiziana Vaisitti, Silvia Deaglio, Luca Laurenti, Aleksandar J. Dimovski, Dimitar G. Efremov

Blood (2022) 140 (22): 2335–2347.

https://doi.org/10.1182/blood.2022016272

Published: 2022

Includes: Supplemental data

Journal Articles

Decreased Apoptotic Priming and Loss of Bcl-2 Dependence Are Functional Hallmarks of Richter's Syndrome

Antonella Rigo, Tiziana Vaisitti, Carlo Laudanna, Matilde Micillo, Flavia Merigo, Alessio Montresor, Andrea Sbarbati, Kevin Mellert, Peter Moeller, Fabrizio Vinante, Silvia Deaglio, Isacco Ferrarini

Blood (2022) 140 (Supplement 1): 1809–1810.

https://doi.org/10.1182/blood-2022-160380

Published: 2022

Journal Articles

Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome

Tiziana Vaisitti, Nicoletta Vitale, Matilde Micillo, Lorenzo Brandimarte, Andrea Iannello, Mauro Giulio Papotti, Ozren Jaksic, Gianluca Lopez, Arianna Di Napoli, Juan Carlos Cutrin, Christian Orlik, Michael Kulke, Andreas Pahl, Silvia Deaglio

Blood (2022) 140 (13): 1565–1569.

https://doi.org/10.1182/blood.2022016211

Published: 2022

Includes: Supplemental data

Journal Articles

Glutamine and CLL: ready for prime time?

Silvia Deaglio

Blood (2022) 140 (6): 528–529.

https://doi.org/10.1182/blood.2022016696

Published: 2022

Journal Articles

A new taxonomy for splenic marginal zone lymphoma

Silvia Deaglio, Tiziana Vaisitti

Blood (2022) 139 (5): 644–645.

https://doi.org/10.1182/blood.2021014198

Published: 2022

Journal Articles

Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome

Tiziana Vaisitti, Nicoletta Vitale, Andrea Iannello, Lorenzo Brandimarte, Matilde Micillo, Mauro Giulio Papotti, Arianna Di Napoli, Christian Orlik, Michael Kulke, Andreas Pahl, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 791.

https://doi.org/10.1182/blood-2021-150280

Published: 2021

Journal Articles

Evidence of a Synergistic Cross-Talk between the B Cell Receptor (BCR) and Nicotinamide Phosphoribosyl Transferase (NAMPT) in Richter's Syndrome Patient-Derived Xenograft Models: Therapeutic Implications

Vincenzo Gianluca Messana, Nicoletta Vitale, Matteo Rovere, Lucia Renzullo, Francesca Arruga, Tiziana Vaisitti, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 250.

https://doi.org/10.1182/blood-2021-150238

Published: 2021

Journal Articles

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Francesca Arruga, Andrea Iannello, Nikolaos Ioannou, Alberto Maria Todesco, Marta Coscia, Riccardo Moia, Gianluca Gaidano, John N. Allan, Richard Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2021-150183

Published: 2021

Journal Articles

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Supriya Chakraborty, Claudio Martines, Fabiola Porro, Ilaria Fortunati, Alice Bonato, Marija Dimishkovska, Silvano Piazza, Brijesh S. Yadav, Idanna Innocenti, Rosa Fazio, Tiziana Vaisitti, Silvia Deaglio, Alberto Zamò, Aleksandar J. Dimovski, Luca Laurenti, Dimitar G. Efremov

Blood (2021) 138 (12): 1053–1066.

https://doi.org/10.1182/blood.2020008276

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio

Blood (2021) 137 (24): 3365–3377.

https://doi.org/10.1182/blood.2020008404

Published: 2021

Includes: Supplemental data

Journal Articles

Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome

Supriya Chakraborty, PhD, Claudio Martines, MS, Fabiola Porro, MS, Ilaria Fortunati, BS, Alice Bonato, BA, Marija Dimishkovska, PhD, Brijesh Yadav, PhD, Idanna Innocenti, MDPhD, Rosa Fazio, BA, Tizianna Vaisitti, PhD, Silvia Deaglio, MD, Alberto Zamò, MD PhD, Aleksandar Dimovski, MD PhD, Luca Laurenti, MD, Dimitar G Efremov, MDPhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136668

Published: 2020

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenografts

Harnessing repressive LEF1/β-catenin complexes to overcome drug resistance in chronic lymphocytic leukemia

PD-1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient-derived xenograft models In Vivo

Toward a new paradigm for CLL treatment

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

CXCR4 Loss Reduces the Local Growth of Richter Syndrome Murine and Patient-Derived Xenograft Models and Impairs BCR and VLA-4 Activation

Chemoresistance pathways in DLBCL

Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo

Decreased Apoptotic Priming and Loss of Bcl-2 Dependence Are Functional Hallmarks of Richter's Syndrome

Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome

Glutamine and CLL: ready for prime time?

A new taxonomy for splenic marginal zone lymphoma

Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome

Evidence of a Synergistic Cross-Talk between the B Cell Receptor (BCR) and Nicotinamide Phosphoribosyl Transferase (NAMPT) in Richter's Syndrome Patient-Derived Xenograft Models: Therapeutic Implications

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only